Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno oncology technologies addressing difficult to treat cancers. The company's proprietary DNase technology targets neutrophil extracellular traps to improve outcomes of existing treatments such as immunotherapies chemotherapy and radiotherapy. Its lead program is a systemic DNase therapy initially aimed at pancreatic carcinoma and colorectal carcinoma as well as other locally…
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno oncology technologies addressing difficult to treat cancers. The company's proprietary DNase technology targets neutrophil extracellular traps to improve outcomes of existing treatments such as immunotherapies chemotherapy and radiotherapy. Its lead program is a systemic DNase therapy initially aimed at pancreatic carcinoma and colorectal carcinoma as well as other locally advanced or metastatic solid tumors. Xenetic Biosciences, Inc. was incorporated under the laws of the State of Nevada in August 2011.
Xenetic Biosciences, Inc. generates revenue primarily through royalty payments received from the licensing of its PolyXen drug delivery platform to partners such as Takeda Pharmaceutical Co Ltd. The company also anticipates potential milestone payments from research collaborations and licensing agreements for its DNase technology and other drug candidates. At present it does not have any approved products on the market and therefore does not record product sales revenue.
Xenetic Biosciences, Inc. operates at an early stage of development within the highly competitive oncology biotechnology sector. Its main competitors include large pharmaceutical companies such as Merck Roche Bristol Myers Squibb and AstraZeneca as well as specialized biotech firms focused on immunotherapy and targeted cancer therapies. The company's competitive advantage lies in its DNase platform which addresses neutrophil extracellular traps a mechanism implicated in tumor progression and resistance to multiple treatment modalities. This mechanistic focus differentiates its pipeline from conventional chemotherapy or checkpoint inhibitor approaches.
Xenetic Biosciences, Inc. serves patients with locally advanced or metastatic solid tumors particularly pancreatic carcinoma and colorectal carcinoma. The company also works with research institutions and clinical partners including Scripps Research the University of Virginia PeriNess and Catalent Pharma Solutions LLC to advance its preclinical and clinical programs. Royalty income is derived from licensees such as Takeda Pharmaceutical Co Ltd which commercializes products incorporating the PolyXen technology.